SCH772984

For research use only. Not for use in humans.

目录号:S7101

SCH772984 Chemical Structure

CAS No. 942183-80-4

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SCH772984发表文献296篇:

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvzTWM2OD1yLkK0JI5O NX;EfFRTOjV|NUC5N|E>
WM-266-4 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED4VIVKSzVyPUKwJI5O M2G1TFI{PjF2OEm4
UACC-62 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\XPHdKSzVyPUOwJI5O NYLzbGI3OjN4MUS4PVg>
Colo-205 NXf1W5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK5TWM2OD1|NjDuUS=> MljINlM3OTR6OUi=
SK-Mel-1 NUTleVdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX3S4FTUUN3ME2zO{BvVQ>? NGDmbmwzOzZzNEi5PC=>
WiDr M{jUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\vb49EUUN3ME2zPUBvVQ>? NWXqNWhwOjN4MUS4PVg>
M14 NH\hRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF25e4pKSzVyPUS3JI5O NVG2eGFCOjN4MUS4PVg>
HT-29 NVL6V2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnyVZZRUUN3ME21NEBvVQ>? MXyyN|YyPDh7OB?=
8505C NHHScnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCTG9IUUN3ME21NEBvVQ>? NV\oXWVuOjN4MUS4PVg>
HT-144 NXLnPZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Ob2lEPTB;NkCgcm0> MlnuNlM3OTR6OUi=
SK-Mel-5 NUPwdpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnuTWM2OD14NjDuUS=> NYXESZEzOjN4MUS4PVg>
A375-SM MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnsNZBKSzVyPUe1JI5O Mn21NlM3OTR6OUi=
SK-Mel-28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzMTWM2OD16NTDuUS=> M1fKUVI{PjF2OEm4
LOX Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonKTWM2OD1zMECgcm0> MlTpNlM3OTR6OUi=
SK-Mel-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFzODDuUS=> M1G1RlI{PjF2OEm4
K1 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj4e3ZWUUN3ME2xN|Ahdk1? M{LxPFI{PjF2OEm4
Hs-695T NI\WPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnLTWM2OD1zNkWgcm0> NXPpdlU1OjN4MUS4PVg>
BHT-101 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH20emNKSzVyPUOwNEBvVQ>? Ml72NlM3OTR6OUi=
RPMI-7951 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zZ[WlEPTB;M{S0JI5O NV7MT2lCOjN4MUS4PVg>
A2058 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN4MDDuUS=> MYqyN|YyPDh7OB?=
SK-Hep-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD1TWM2OD1zNEKyJI5O NGG3NIszOzZzNEi5PC=>
A673 NXPjZVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;KTWM2OD1|MECxJI5O MUmyN|YyPDh7OB?=
DBTRG-05MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HtfmlEPTB;M{CwNUBvVQ>? NXfVcGU2OjN4MUS4PVg>
SW-626 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\qemlEPTB;M{Ogcm0> NHr6OmQzOzZzNEi5PC=>
LoVo M174TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLYN|NiUUN3ME20O{BvVQ>? MoC4NlM3OTR6OUi=
MiaPaCa MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTV|IH7N MnfFNlM3OTR6OUi=
SW-620 NXSwTIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK5WpBCUUN3ME2xNFQhdk1? NF\PdVQzOzZzNEi5PC=>
CAPAN-1 NYPJSVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD2ZmoxUUN3ME2xNFQhdk1? MVqyN|YyPDh7OB?=
SW-527 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XJemlEPTB;MUKxJI5O M3TFNVI{PjF2OEm4
HCT-116 M4LWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInDcIxKSzVyPUGyPEBvVQ>? MYmyN|YyPDh7OB?=
SW-480 NXjkZ|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TvZ2lEPTB;MU[1JI5O NWi0Nm5pOjN4MUS4PVg>
HPAC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofzTWM2OD1zN{Cgcm0> M1jPWlI{PjF2OEm4
OVCAR-5 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn3N2tKSzVyPUKwPEBvVQ>? Mk\INlM3OTR6OUi=
AsPc-1 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5MDDuUS=> Ml[2NlM3OTR6OUi=
A549 NHq4OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nFbGlEPTB;M{K2JI5O M{noXlI{PjF2OEm4
SNU-1 NE\Oc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN3NDDuUS=> NXKyfYdNOjN4MUS4PVg>
HOP62 NH7IU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjGTWM2OD14N{[gcm0> MX6yN|YyPDh7OB?=
H23 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknxTWM2OD1zMECwJI5O NE\SdYUzOzZzNEi5PC=>
MB-231 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTuZ3RKSzVyPUGwNFAhdk1? MmHUNlM3OTR6OUi=
SU.86.86 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFyMEGgcm0> MXqyN|YyPDh7OB?=
CFPAC-1 M4fYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDpc2RKSzVyPUGwNFEhdk1? M4CwN|I{PjF2OEm4
A427 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPV[YNKSzVyPUG0N|Mhdk1? NVO4bXI{OjN4MUS4PVg>
MDAH-2774 NGP3SlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLEbmhKSzVyPUK2OVchdk1? NXjm[JhROjN4MUS4PVg>
NCI-H157 M4TXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf1XlJKSzVyPUOwNFAhdk1? NVy3eItDOjN4MUS4PVg>
HTB-177 NH3QV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHWb4o5UUN3ME2zNFAxKG6P MorPNlM3OTR6OUi=
UM-UC-3 M3X2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS3Z5lKSzVyPUOwNFEhdk1? MmD6NlM3OTR6OUi=
HCT-8 NH7DeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr0OGNXUUN3ME2zNFAyKG6P NIX6OmEzOzZzNEi5PC=>
Panc-1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rpPWlEPTB;M{CwNUBvVQ>? Mn20NlM3OTR6OUi=
DLD-1 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNyMEGgcm0> NUC4OJN{OjN4MUS4PVg>
HCT-15 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:0ZZhTUUN3ME2zNFAyKG6P NXPuToc4OjN4MUS4PVg>
HL-60 NHrMS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNyIH7N M2LqXFI{PjF2OEm4
SK-Mel-2 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN2IH7N NV\yXJJlOjN4MUS4PVg>
RD NEC3SpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF{MzDuUS=> NXHvU3hJOjN4MUS4PVg>
HT-1197 M3;FZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnSmlEPTB;M{G2JI5O NEjycmgzOzZzNEi5PC=>
Molt-3 NUHDSY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHtdXpKSzVyPU[wNEBvVQ>? NIrFboszOzZzNEi5PC=>
PA-1 M17UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmxdIJuUUN3ME2xNFAyKG6P Mln1NlM3OTR6OUi=
Molt-4 NI\hSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNyMEGgcm0> M3fmO|I{PjF2OEm4
NCI-H292 NV3qRVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTlyIH7N M{TJUVI{PjF2OEm4
A2780 NGLaUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\Nb2lEPTB;MUSzJI5O NH7LTVUzOzZzNEi5PC=>
IGROV-1 NHG2T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;hb2lEPTB;MUS2JI5O NU\0dGxJOjN4MUS4PVg>
SK-N-SH MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF3MDDuUS=> M2\0RVI{PjF2OEm4
N-87 NEHsTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO0[2VFUUN3ME2zNFchdk1? MnrENlM3OTR6OUi=
H322 NHHMVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTN{NTDuUS=> NWmwUlhPOjN4MUS4PVg>
H716 NEXh[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnQfm9KSzVyPUOzOEBvVQ>? MkXsNlM3OTR6OUi=
TT NFjRemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRyNjDuUS=> MYqyN|YyPDh7OB?=
Caki-1 M1uwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTR3MDDuUS=> M3zwOlI{PjF2OEm4
5637 M{\0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T6Z2lEPTB;NkGwJI5O NVfGOGFsOjN4MUS4PVg>
MB-453 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\BOVNKSzVyPU[3NkBvVQ>? NVu0flcyOjN4MUS4PVg>
RT-4 NWrNeItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LZZ2lEPTB;OEGwJI5O NXrVe2k5OjN4MUS4PVg>
HOP92 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[yVGlEPTB;OEKwJI5O MnizNlM3OTR6OUi=
KG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Be5BKSzVyPUmwNEBvVQ>? NWnZdlhbOjN4MUS4PVg>
Hs-294T MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MleyTWM2OD17NEWgcm0> NV7HUndROjN4MUS4PVg>
SF-539 NWjzRoI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3hS4RKSzVyPUGwNFAhdk1? NF\BPZozOzZzNEi5PC=>
U-251 NHnPdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFyMECgcm0> Mm[2NlM3OTR6OUi=
MB-468 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFyMECgcm0> NEjnWIIzOzZzNEi5PC=>
HS746T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFyMECgcm0> MWSyN|YyPDh7OB?=
SCABER MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliyTWM2OD1zMECwJI5O MkLGNlM3OTR6OUi=
MCF-7 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfnTWM2OD1zMECxJI5O M3HzdFI{PjF2OEm4
CHL-1 NWHK[oVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeyU4NKSzVyPUG0OlAhdk1? MYKyN|YyPDh7OB?=
U87MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPlTWM2OD1{MECwJI5O NIPab2IzOzZzNEi5PC=>
SJCRH30 NFXBUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;NZY5bUUN3ME2yNFAzKG6P NXvGXZVZOjN4MUS4PVg>
ES-2 NX[ydXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PXUmlEPTB;Mk[1PUBvVQ>? MojjNlM3OTR6OUi=
HT-1376 M1;2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\UWZlyUUN3ME2yPFAxKG6P MX[yN|YyPDh7OB?=
A172 M1\JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSy[HhKSzVyPUOwNFAhdk1? Ml7KNlM3OTR6OUi=
769P MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX6T5o5UUN3ME2zNFAxKG6P NVXDTVdjOjN4MUS4PVg>
NCI-H520 NVfldIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH23[pRKSzVyPUOwNFAhdk1? NFzVdmEzOzZzNEi5PC=>
DU145 NFr2NoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxUWlEPTB;M{CwNEBvVQ>? MkLKNlM3OTR6OUi=
K562 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WxN2lEPTB;M{CwNEBvVQ>? NGXMZ2EzOzZzNEi5PC=>
U-937 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fnXWlEPTB;M{CwNEBvVQ>? MmXpNlM3OTR6OUi=
A204 NF\oXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tTm1KSzVyPUOwNFEhdk1? M33XTFI{PjF2OEm4
DAOY MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTUTWM2OD1|MECxJI5O NXX1OGFqOjN4MUS4PVg>
SF-268 NUj4VoR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n1NWlEPTB;M{CwNUBvVQ>? MV:yN|YyPDh7OB?=
SF-295 NEnwV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PMOmlEPTB;M{CwNUBvVQ>? NH3TT24zOzZzNEi5PC=>
SNB-19 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNyMEGgcm0> NHS1NVMzOzZzNEi5PC=>
SNB-75 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkTWM2OD1|MECxJI5O NEDifpAzOzZzNEi5PC=>
U373-MG NXzkSlZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEixToZKSzVyPUOwNFEhdk1? NFH3UYwzOzZzNEi5PC=>
786-O Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXzOYZkUUN3ME2zNFAyKG6P MVKyN|YyPDh7OB?=
A498 NGPPb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNyMEGgcm0> MY[yN|YyPDh7OB?=
ACHN M3HqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPNUXVKSzVyPUOwNFEhdk1? M3:5fFI{PjF2OEm4
EKVX MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;yTWM2OD1|MECxJI5O NHfpOIMzOzZzNEi5PC=>
H226 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNyMEGgcm0> M2jibVI{PjF2OEm4
H522 NYnrPFluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jwcGlEPTB;M{CwNUBvVQ>? MWeyN|YyPDh7OB?=
HeLa M2nKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNyMEGgcm0> NIXkb|czOzZzNEi5PC=>
SK-OV-3 NEfmfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHi[5RrUUN3ME2zNFAyKG6P M3rYRlI{PjF2OEm4
Ln Cap NUjhUpRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XTbmlEPTB;M{CwNUBvVQ>? NG\meI0zOzZzNEi5PC=>
PC3 NV7vTld5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TD[mlEPTB;M{CwNUBvVQ>? M3H0NFI{PjF2OEm4
SNU-16 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1[mlEPTB;M{CwNUBvVQ>? Mk\NNlM3OTR6OUi=
FTC-133 M{XKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOepFiUUN3ME2zNFAyKG6P M2DxZlI{PjF2OEm4
Ro82-W-1 M1zvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYPHNKSzVyPUOwNFEhdk1? NHmzXnQzOzZzNEi5PC=>
Daudi MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nw[2lEPTB;M{CwNUBvVQ>? MWeyN|YyPDh7OB?=
Jijoye MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD1|MECxJI5O NWnwbGZGOjN4MUS4PVg>
Jurkat MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNyMEGgcm0> MYeyN|YyPDh7OB?=
J-82 NFfidldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\wdXcxUUN3ME2zNFAyKG6P M335RVI{PjF2OEm4
TCC-SUP NXHLZpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNyMEGgcm0> MoHVNlM3OTR6OUi=
BT-474 NXLBVFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDhXGo6UUN3ME2zNFAyKG6P MXyyN|YyPDh7OB?=
ZR-75-1 NYDGNZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPwTWM2OD1|MECxJI5O M{Pvd|I{PjF2OEm4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cyclin B1 / cyclin D1 / p21; 

PubMed: 26725216     


Cells treated as above were collected for western blot for total cyclin B1, cyclin D1 and p21, and of phosphorylated, inactivated RB (S807/811; pRB). Western blot for pERK was done to verify SCH772984 inhibition; β-actin was the loading control.

pRSK / pERK / pAKT / pMEK; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984, then evaluated by western blot with phospho-specific antibodies for RSK (T395/S363; pRSK), MEK1/2 (S217/221; pMEK), AKT (S473; pAKT), and ERK (T202/Y204; pERK). Total RSK, ERK, AKT, MEK and β-actin were also analyzed. Data are representative of three independent experiments.

DUSP1 / DUSP4 / DUSP6; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for DUSP1, DUSP4, DUSP6 and β-actin.

pCRAF(S338, S289, S296, S301); 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for pCRAF (S338), pCRAF (S289/296/301), total CRAF and β-actin.

Aurora B / ETS1 / ETS2; 

PubMed: 26725216     


Cells were treated with vehicle or SCH772984 for 7 days, then immunoblotted for Aurora B, MYC, ETS1 or ETS2, and β-actin. Data are representative of three independent experiments.

26725216
Growth inhibition assay
Cell viability; 

PubMed: 30118499     


NCI-H747, SW837, SW480, and SW620 cells were treated with the ERK inhibitor SCH772984 at indicated concentrations for 72 hours. Dimethyl sulfoxide (DMSO) (0.01%) was used as the control treatment. Each data point represents the mean of five replicates; error bars indicate one SD.

30118499
Immunofluorescence
TOMM20; 

PubMed: 30833752     


Mitochondrial morphologies of PDAC cells treated with SCH772984 (ERKi, 1 µM) for 24 h. Green, Anti-TOMM20; blue, DAPI; scale bar, 20 μm.

pERK1/2; 

PubMed: 30213106     


After treatment with 10 µM of the ERIK1/2 inhibitors, the expression of p-ERK1/2 protein in HeLa cells was detected using immunofluorescence (400×), bar = 50 μm.

30833752 30213106
体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

- 合并
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 裸鼠
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID